HaemaLogiX announces issuance of Australian patent for LMA
The provisional patent application filed in 2017 “Anti-lambda myeloma antigen (LMA) binding proteins to treat LMA-expressing cancer and autoimmune disorders” has been granted by IP Australia. The application is directed towards anti-lambda myeloma antigen binding proteins, which may be useful for treating disorders associated with aberrant proliferation of lambda restricted B-cell malignancies and/or their precursors.
The inventors identified a selection of human antibodies that bind and kill LMA-positive cell lines. They identified human antibodies with heavy chain modifications that direct preferential binding to LMA (a cell-surface antigen) over free lambda light chain (a serum antigen). These modifications may be incorporated into various binding proteins to preferentially target cells expressing LMA. Such structurally unique binding proteins may be particularly effective at mediating the targeted killing of cells expressing LMA via the dual mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
This patent was granted in Australia on 11 December 2020 and is also under review in other jurisdictions.